Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia (PRECAVER)
Evaluate the benefit (rate of adherence to the treatment), based on the LDL-C reduction in the group that will be exposed to the program of reinforcement of orientation aimed to the patients, compared to the control group, both in previous use of rosuvastatin.
Patients With Dyslipidemia
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Education and Awareness Program Targeting the Assessment of Adherence of the Treatment of Dyslipidemia|
- Assess the LDL-C reduction in the group exposed to the educational program compared to the group with routine orientation
- Assess cardiovascular risk through Framingham's score, · · Identify personal characteristics of the study population regarding their health, compile demographic characteristics regarding education, economic and cultural status.
|Study Start Date:||November 2007|
|Study Completion Date:||September 2010|
|Primary Completion Date:||September 2010 (Final data collection date for primary outcome measure)|
Receives treatment with rosuvastatin, according to International and National Guidelines on hypercholesterolemia.
Receives the same treatment as group 1 and information on health improvement, diet and exercises applied to the disease that is being treated. The positive impact of the information upon treatment will be statistically evaluated.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00557778
|Campinas, Sao Paulo, Brazil|
|Study Director:||Jose Eduardo Neves, MD||AstraZeneca Brazil Ltda|
|Principal Investigator:||Francisco Jose Saraiva, MD||PUC-Campinas|